Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2001
10/10/2001EP0804233B1 Methods for the cultivation of infectious laryngotracheitis virus and egg drop syndrome virus
10/10/2001EP0770071B1 Sulfonamide derivatives of azolones anti-helicobacter agents
10/10/2001CN1317043A Polypeptides and polynucleotides from coagulase-negative staphylocoui
10/10/2001CN1317008A Novel antibacterial compounds
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316991A Azetidine derivatives, preparation and medicines containing them
10/10/2001CN1316431A Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
10/10/2001CN1316419A Arenesulfonyl amino-iso hydroximic acid derivative
10/10/2001CN1316269A Medicine for treating viral hepatitis
10/10/2001CN1316254A Injection for antivirus promoting immunity, and leaukogenic and its preparing process
10/10/2001CN1316253A Exterior-applied medicine for treating beriberi and its preparing process
10/10/2001CN1316250A Kuaiban injection-treating hog cholera blood spots
10/10/2001CN1316247A Clamycin injection and its preparing process
10/10/2001CN1072654C Benzamide derivative, composition containing said derivative and use thereof
10/10/2001CN1072506C Improved diplococuus meninigitidis polysaccharide conjugate vaccine
10/10/2001CA2343344A1 Erythromycin a derivatives
10/09/2001US6300495 Process for the preparation of a metal salt of clavulanic acid
10/09/2001US6300358 Administering benzydamine or a physiologically acceptable acid addition salt for therapy of condition caused by tumor necrosis factor
10/09/2001US6300351 For inhibiting human immunodeficiency virus-1 (hiv-1) reverse transcriptase
10/09/2001US6300341 2-substituted heterocyclic sulfonamides
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300318 Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
10/09/2001US6300316 C-4 substituted macrolide antibiotics
10/09/2001US6300118 Plasmids comprising a genetically altered feline immunodeficiency virus genome
10/09/2001US6300102 Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
10/09/2001US6300097 A polypeptide; therapy and diagnosis of bacterial infections; upper respiratory infections, toxic shock syndrome, septic arthritis and intestinal disorders
10/09/2001US6300057 Melanins with improved ability to inhibit HIV replication
10/09/2001US6299925 Effervescent green tea extract formulation
10/09/2001US6299883 Tarf
10/09/2001US6299882 UL54.5 of Marek's disease virus (MDV)
10/09/2001US6299877 Used in therapy
10/09/2001US6299874 Administering vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to live virus; neutralizing factor is selected from the group consisting of antibodies and antibody fragments
10/09/2001US6299872 Administering combination of interferon alpha and ribavirin to reduce symptoms of hepatitis c infection
10/09/2001US6299869 Human interferon-epsilon: a type I interferon
10/09/2001CA2325541C Extended release formulations of erythromycin derivatives
10/09/2001CA2082825C Inhibition of viral infection
10/09/2001CA1341304C Pharmaceutical composition for the prevention of sexually transmitted diseases
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/07/2001CA2304869A1 Method of medical treatment using uric acid or precursors thereof
10/04/2001WO2001073104A1 Beta-glucans from filamentous fungi
10/04/2001WO2001073080A2 Recombinant iron uptake proteins
10/04/2001WO2001073078A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073033A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001073018A2 Human tap-like protein (transporter associated in antigen processing/presentation)
10/04/2001WO2001072993A1 Tlr/cd14 binding inhibitor
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072848A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072831A2 Immunoregulator
10/04/2001WO2001072782A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus
10/04/2001WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001WO2001072778A2 Method of identifying inhibitors of tie-2
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072740A1 Substituted 1-(4-aminophenyl) triazoles and their use as anti-inflammatory agents
10/04/2001WO2001072738A1 Quinolonecarboxylic acid derivative
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
10/04/2001WO2001072705A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072701A1 Ceramide derivatives and method of use
10/04/2001WO2001072340A1 Aids virus vaccine with the use of sendai virus vector
10/04/2001WO2001072337A1 Proteins for use as carriers in conjugate vaccines
10/04/2001WO2001072334A2 Methods for treating disease with antibodies to cxcr3
10/04/2001WO2001072330A2 Method for immunostimulation using binding agents for the fc rec eptor of immunoglobulin a and for cancer cells or infections antigen
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072323A2 Use of insulin for the treatment of cartilagenous disorders
10/04/2001WO2001072322A2 High dosage parenteral administration of lactoferrin
10/04/2001WO2001072312A1 Antiviral therapeutic composition and treatment
10/04/2001WO2001072304A1 A novel anti-microbial composition and method for producing the same
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072294A2 Method of treating hepatitis delta viral infection
10/04/2001WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
10/04/2001WO2001072277A2 Immunotherapeutic methods and compositions
10/04/2001WO2001049688A8 Purine derivatives, process for their preparation and use thereof
10/04/2001WO2001022990A3 Methods related to immunostimulatory nucleic acid-induced interferon
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001019335A3 Composition to be administered through mucous membrane
10/04/2001WO2001019322A3 Use of csaids in rhinovirus infection
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2001013956A3 Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
10/04/2001WO2001012214A3 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
10/04/2001WO2001008701A3 Invasive bacteria based viral vaccines
10/04/2001WO2000078343A8 Method for treating chronic hbv infection
10/04/2001WO2000062795A9 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS
10/04/2001WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
10/04/2001WO2000021556A9 Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
10/04/2001WO2000015178A9 Computer implemented pharmacokinetics method and program
10/04/2001WO1999055860A8 Host-encoded protein expressed on marek's disease (mdv)-infected cells and antibody thereto
10/04/2001US20010027565 Capable of binding envelope protein of hepatitis virus; therapy and/or diagnostic tool for hepatitis infection
10/04/2001US20010027212 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
10/04/2001US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents
10/04/2001US20010027184 Serine/threonine protein kinase (H-SGK2)
1 ... 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 ... 1798